zilucoplan gMG
Selected indexed studies
- Zilucoplan: First Approval. (Drugs, 2024) [PMID:38093160]
- ** (, 2025) [PMID:40100975]
- Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. (JAMA Neurol, 2020) [PMID:32065623]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis. (2024) pubmed
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis. (2024) pubmed
- Zilucoplan: First Approval. (2024) pubmed
- PMID:40100975 (2025) pubmed
- Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. (2020) pubmed
- Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. (2025) pubmed
- Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. (2024) pubmed
- Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study. (2025) pubmed
- Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG). (2025) pubmed
- Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study. (2025) pubmed